Table_4.xls (13.5 kB)

Treatment-emergent adverse events occurring in more than one patient.

Name: Treatment-emergent adverse events occurring in more than one patient.
Published: 2014-10-06T03:29:27+00:00
License: https://creativecommons.org/licenses/by/4.0/
Keywords: 3 hours, 12 patients, mg, Multicenter Phase, safety differences, Obatoclax Mesylate Administered, aml, Initial obatoclax dose, Complete response, objective response, chemotherapy modalities, 24 hours, grade 3 neurologic DLTs, response rate.ResultsIn phase, Phase II, Myeloid leukemia, phase II study, mtd, nct

dataset

posted on 2014-10-06, 03:29 authored by Aaron D. Schimmer, Azra Raza, Thomas H. Carter, David Claxton, Harry Erba, Daniel J. DeAngelo, Martin S. Tallman, Carolyn Goard, Gautam Borthakur

Treatment-emergent adverse events occurring in more than one patient.

History

Usage metrics

Categories

Keywords

Licence

Exports